ACET Adicet Bio, Inc. Stock Quote

ACET [NASD]

Index	-	P/E	-	EPS (ttm)	-4.45	Insider Own	11.92%	Shs Outstand	31.82M	Perf Week	-2.62%
Market Cap	219.82M	Forward P/E	-	EPS next Y	-2.21	Insider Trans	-3.14%	Shs Float	28.05M	Perf Month	1.88%
Income	-55.90M	PEG	-	EPS next Q	-0.44	Inst Own	66.90%	Short Float	1.65%	Perf Quarter	-25.32%
Sales	9.30M	P/S	23.64	EPS this Y	70.30%	Inst Trans	4.35%	Short Ratio	3.09	Perf Half Y	-50.94%
Book/sh	7.18	P/B	0.98	EPS next Y	-10.50%	ROA	-26.20%	Target Price	-	Perf Year	-47.70%
Cash/sh	6.69	P/C	1.05	EPS next 5Y	29.10%	ROE	-32.30%	52W Range	6.25 - 17.80	Perf YTD	-49.82%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-33.10%	52W High	-60.62%	Beta	2.44
Dividend %	-	Quick Ratio	10.30	Sales past 5Y	-	Gross Margin	-	52W Low	12.16%	ATR	0.47
Employees	81	Current Ratio	10.30	Sales Q/Q	-49.50%	Oper. Margin	-	RSI (14)	40.31	Volatility	6.03% 5.83%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	88.90%	Profit Margin	-	Rel Volume	0.24	Prev Close	7.05
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	149.22K	Price	7.01
Recom	1.40	SMA20	-8.09%	SMA50	-6.87%	SMA200	-41.09%	Volume	35,389	Change	-0.57%

May-18-21

Initiated

BTIG Research

Buy

$34

Apr-23-21

Initiated

H.C. Wainwright

Buy

$27

Apr-14-21

Initiated

Canaccord Genuity

Buy

$28

Apr-08-21

Initiated

Guggenheim

Buy

$22

Nov-04-20

Initiated

B. Riley Securities

Buy

$30

Oct-27-20

Initiated

JMP Securities

Mkt Outperform

$30

Oct-16-20

Initiated

Wedbush

Outperform

$25

Sep-13-21 08:00AM	Twist Bioscience Collaborates with Adicet Bio to Accelerate Discovery of Gamma Delta T Cell Cancer Therapeutics Business Wire
08:00AM	Adicet Bio Collaborates with Twist Bioscience to Accelerate Discovery of Gamma Delta T Cell Cancer Therapeutics GlobeNewswire
Sep-02-21 04:53PM	Adicet Bio to Participate in Upcoming Investor Conferences GlobeNewswire
Aug-12-21 04:01PM	Adicet Reports Second Quarter 2021 Financial Results and Provides Business Updates GlobeNewswire
Aug-02-21 07:00AM	Adicet Bio to Participate in Upcoming Investor Conferences GlobeNewswire
Jul-30-21 10:35AM	Is Adicet Bio Inc. (ACET) A Good Stock To Buy? Insider Monkey
Jul-15-21 07:00AM	Adicet Bio Announces Formation of Scientific Advisory Board GlobeNewswire
Jun-28-21 07:00AM	Adicet Bio Added to the Russell 2000® Index GlobeNewswire
May-18-21 04:10PM	Adicet Bio to Participate in Upcoming Investor Conferences GlobeNewswire
May-17-21 07:01AM	Adicet Reports First Quarter 2021 Financial Results and Provides Business Updates GlobeNewswire
Apr-29-21 07:00AM	Adicet Bio to Participate in Fireside Chat at the 7th Annual Truist Securities Life Sciences Summit GlobeNewswire +5.42%
Apr-15-21 07:00AM	Adicet Bio to Participate in the Canaccord Genuity 2021 Horizons in Oncology Virtual Conference GlobeNewswire
Apr-13-21 07:00AM	Adicet Bio Appoints Dr. Blake Aftab as Vice President of Research GlobeNewswire
Mar-11-21 04:10PM	Adicet Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update GlobeNewswire
Mar-10-21 07:00AM	Adicet Bio Announces Initiation of its First-in-Human Phase 1 Trial of ADI-001 for the Treatment of B Cell Non-Hodgkin's Lymphoma PR Newswire
Mar-04-21 04:01PM	Adicet Bio Appoints Dr. Andrew Sinclair to its Board of Directors GlobeNewswire -11.55%
Feb-16-21 07:00AM	Adicet Bio, Inc. Announces Closing of $152 Million Public Offering and Concurrent Private Placement and Exercise in Full of the Underwriters Option to Purchase Additional Shares GlobeNewswire
Feb-11-21 07:00AM	Adicet Bio to Participate in Upcoming Investor Conferences GlobeNewswire
Feb-10-21 07:51AM	Adicet Bio, Inc. Announces Pricing of $135 Million Public Offering of Common Stock and Concurrent Private Placement GlobeNewswire +21.99%
Feb-09-21 04:04PM	Adicet Bio, Inc. Announces Proposed Public Offering of Common Stock and Concurrent Private Placement GlobeNewswire
Jan-07-21 07:00AM	Adicet Bio to Participate in Upcoming Investor Conferences GlobeNewswire
Dec-15-20 11:19PM	We're Hopeful That Adicet Bio (NASDAQ:ACET) Will Use Its Cash Wisely Simply Wall St.
Dec-08-20 07:00AM	Adicet Bio to Participate in Fireside Chat at JMP Securities Hematology Summit GlobeNewswire
Dec-07-20 11:37PM	Is ACET A Good Stock To Buy Now? Insider Monkey -5.23%
Dec-01-20 07:00AM	Adicet Announces Appointment of Dr. Bastiano Sanna to its Board of Directors GlobeNewswire
Nov-06-20 07:00AM	Adicet Bio to Participate in Upcoming Investor Conferences GlobeNewswire
Nov-05-20 04:10PM	Adicet Reports Third Quarter 2020 Financial Results and Provides Business Update GlobeNewswire +5.96%
Oct-26-20 04:10PM	Adicet Appoints Don Healey, Ph.D., as Chief Technology Officer GlobeNewswire
Oct-22-20 07:00AM	Adicet Announces FDA Clearance of IND Application for First-in-Class Allogeneic CAR Gamma-Delta T Cell Therapy GlobeNewswire
Oct-01-20 04:10PM	Adicet Bio to Present at the Jefferies Cell Therapy Summit GlobeNewswire
Sep-22-20 10:42PM	Adicet Bio, Inc. Determines Not to Proceed with Public Offering of Common Stock GlobeNewswire -24.52%
Sep-21-20 07:00AM	Adicet Bio, Inc. Announces Proposed Public Offering of Common Stock GlobeNewswire -37.01%
Sep-18-20 04:10PM	Adicet Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) GlobeNewswire +32.84%
Sep-16-20 07:00AM	Adicet Bio Appoints Nick Harvey as Chief Financial Officer GlobeNewswire
Sep-15-20 04:10PM	Adicet Bio to Present at the Cantor Virtual Global Healthcare Conference GlobeNewswire

Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase 1 clinical study for the treatment of non-Hodgkin's lymphoma. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors, including hepatocellular carcinoma, gastric cancer, and squamous cell carcinoma of the lung. The company is based in Boston, Massachusetts.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Schor Chen	President & CEO	Jun 16	Sale	10.53	16,466	173,443	74,841	Jun 21 04:25 PM
Jakobovits Aya	Director	Jun 15	Sale	11.16	3,847	42,919	215,883	Jun 17 06:08 PM
Galimi Francesco	SVP & Chief Medical Officer	Jun 04	Option Exercise	5.97	6,983	41,689	6,983	Jun 08 09:35 PM
Schor Chen	President & CEO	Jun 03	Sale	12.06	16,466	198,499	82,325	Jun 07 07:12 PM
Jakobovits Aya	Director	May 20	Sale	14.23	1,792	25,498	217,806	May 20 07:28 PM
Schor Chen	President & CEO	May 19	Sale	13.45	16,466	221,436	89,809	May 21 04:34 PM
Jakobovits Aya	Director	May 18	Sale	14.05	6,208	87,249	218,699	May 20 07:28 PM
Jakobovits Aya	Director	May 12	Sale	13.23	10,000	132,332	221,806	May 14 04:33 PM
Schor Chen	President & CEO	May 05	Sale	14.22	16,466	234,222	97,293	May 07 04:02 PM
Schor Chen	President and CEO	Apr 20	Sale	12.01	16,466	197,676	104,777	Apr 22 04:34 PM
Schor Chen	President and CEO	Apr 06	Sale	13.04	16,466	214,700	112,261	Apr 08 04:37 PM
Schor Chen	President and CEO	Mar 16	Sale	15.34	16,466	252,558	127,229	Mar 18 09:55 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience